Recombinant Human Syndecan-1 (SDC1) Protein (hFc)

Name: Recombinant Human Syndecan-1 (SDC1) Protein (hFc)
Brand: Beta LifeScience
SKU: BLC-10926P
Availability: InStock

Greater than 85% as determined by SDS-PAGE.

Collections: All products, Antibody / cell therapy targets, Antibody therapeutic / adc target proteins, Car-nk targets proteins, High-quality recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Syndecan-1 (SDC1) Protein (hFc) is produced by our Mammalian cell expression system. This is a protein fragment.
Purity	Greater than 85% as determined by SDS-PAGE.
Uniprotkb	P18827
Target Symbol	SDC1
Synonyms	CD_antigen; CD138; CD138 antigen; heparan sulfate proteoglycan fibroblast growth factor receptor; SDC; Sdc1; SDC1_HUMAN; SYND1; Syndecan 1; Syndecan; syndecan proteoglycan 1; Syndecan-1
Species	Homo sapiens (Human)
Expression System	Mammalian cell
Tag	C-hFc
Target Protein Sequence	QIVATNLPPEDQDGSGDDSDNFSGSGAGALQDITLSQQTPSTWKDTQLLTAIPTSPEPTGLEATAASTSTLPAGEGPKEGEAVVLPEVEPGLTAREQEATPRPRETTQLPTTHLASTTTATTAQEPATSHPHRDMQPGHHETSTPAGPSQADLHTPHTEDGGPSATERAAEDGASSQLPAAEGSGEQDFTFETSGENTAVVAVEPDRRNQSPVDQGATGASQGLLDRKEVLG
Expression Range	23-254aa
Protein Length	Partial
Mol. Weight	51.3 kDa
Research Area	Cancer
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Cell surface proteoglycan that bears both heparan sulfate and chondroitin sulfate and that links the cytoskeleton to the interstitial matrix. Regulates exosome biogenesis in concert with SDCBP and PDCD6IP.
Subcellular Location	Membrane; Single-pass type I membrane protein. Secreted. Secreted, extracellular exosome.
Protein Families	Syndecan proteoglycan family
Database References	HGNC: 10658 OMIM: 186355 KEGG: hsa:6382 STRING: 9606.ENSP00000254351 UniGene: PMID: 30151336 Study demonstrated that miR494 is able to downregulate SDC1 expression, thereby inhibiting the progression of pancreatic cancer. PMID: 29956739 High serum SDC1 expression is associated with chemotherapy-resistance in castration-resistant prostate cancer. PMID: 29628317 E-Cadherin and epithelial syndecan-1 were more highly expressed in intraluminal/luminal unicystic ameloblastoma than in mural unicystic ameloblastoma and solid/multicystic ameloblastoma, whereas the stromal expression of syndecan-1 was higher in mural unicystic ameloblastoma and solid/multicystic ameloblastoma. PMID: 29850393 evamisole inhibited CD138 expression and affected the levels of IL-6 in a dose-dependent manner. The results of the present study add new dimension to levamisole's mode of action as inhibitor of CD138 and IL-6 and as an antiapoptotic agent. PMID: 29798960 serum level higher in control group than in early-onset or late-onset pre-eclampsia PMID: 28574293 syndecan-1 levels were associated with not only the severity of illness and mortality but also disseminated intravascular coagulation development in sepsis, suggesting that syndecan-1 could be a predictive marker of disseminated intravascular coagulation PMID: 28843664 our findings revealed that SDC1 suppressed EMT via the modulation of the ERK signaling pathway that, in turn, negatively affected the invasiveness of human oral cancer cells. Our results provided useful evidence about the potential use of SDC1 as a molecular target for therapeutic interventions in human oral cancer. PMID: 29484435 The positive correlation between soluble Syndecan-1 levels and breast cancer tumor size in the present study highlights the importance of this molecule in the breast tumor progression and their significance as tumor biomarkers. PMID: 28382590 our results identify the CD63-syntenin-1-ALIX complex as a key regulatory component in post-endocytic HPV trafficking. PMID: 27578500 abrogation of nuclear translocation of syndecan-1 resulted in a set of changes clustering in distinct patterns, which highlighted the functional importance of nuclear syndecan-1 in hampering cell proliferation and the cell cycle PMID: 29216821 findings support a key role for Sdc1 in modulating pulmonary protection by FFP after hemorrhagic shock. PMID: 28107214 S1P induces advanced tumor phenotypes of hepatocellular carcinoma via establishing an MMP-7/syndecan-1/TGF-beta1 autocrine loop PMID: 27556509 There was a close correlation between the expression of IL-17 and syndecan-1 in nasal mucosa epithelial cells, glandular epithelial cells, and inflammatory cells, suggesting that IL-17 and syndecan-1 may play a role, and interact with each other, in the pathogenesis of non- eosinophilic chronic rhinosinusitis with nasal polyps. PMID: 28585128 the present study showed that serum Syndecan-1 might be a reliable marker for monitoring disease activity and renal activity in children with JSLE and lupus nephritis. PMID: 27838471 The above suggest that radiation-mediated premature senescence and invasive tumor cells, alone or in combination, enhance SDC1 expression in breast stromal fibroblasts, a poor prognostic factor for cancer growth, and that TGF-beta plays a crucial role in this process. PMID: 27434331 A syndecan-1 level >/=40 ng/mL identified trauma patients with significantly worse outcomes, despite admission physiology similar to those without the condition. PMID: 28579548 MiR-331-3p-mediated miRNA maturation and enhanced epithelial-to-mesenchymal transition via effects on TGF-beta/Smad 4 and Dicer are essential for the development of prostate cancer mediated by syndecan-1. PMID: 26259043 The heparanase/syndecan1 axis in gallbladder carcinoma cells plays an important role in the invasion and metastasis, thus providing a new therapeutic target. PMID: 28351285 Syndecan-1 acts as a novel tissue biomarker and a modulator of CSC phenotype of triple negative IBC via the IL-6/STAT3, Notch and EGFR signaling pathways, thus emerging as a promising therapeutic target for IBC. PMID: 28270211 Hepatitis C virus infection downregulates Synd-1 and upregulates Xylt 2 expression, likely contributing to a major glycocalyx reshuffle within days of infection. PMID: 27930836 Soluble Sdc1 is significantly lower before the clinical onset of preeclampsia, with reduced expression of Sdc1 in the delivered placenta, suggesting a role for glycocalyx disturbance in preeclampsia pathophysiology. PMID: 27299886 Heparanase has emerged as a major regulator of cancer by degrading heparan sulfate thereby influencing multiple signaling pathways that control gene expression, syndecan shedding and cell behavior. (Review) PMID: 27758044 Study provides robust evidence in favor of the additional baseline soluble CD138 prognostic value for OS, in mCRC patients. A simple biological scoring system is proposed including LDH and CD138 binary status values. PMID: 27472156 it is not appropriate to assume that CD138 expression in urothelial carcinomas is specific for plasmacytoid variants PMID: 27305940 epithelial cytoplasmic expression of maspin and CD138 may have a significant role in tumorigenesis in ovarian high-grade serous carcinomas and clear cell carcinomas; these markers may regulate tumor cell proliferation, and their significant correlation to each other may suggest that CD138 probably induces maspin expression to protect tumor growth factors from being lysed by proteolytic enzymes PMID: 26526579 High syndecan level is associated with sepsis. PMID: 26953518 Systemic sclerosis (SSc) patients with elevated serum syndecan-1 levels had higher prevalence of telangiectasia, elevated right ventricular systolic pressure and decreased diffuse capacity of the lung for carbon monoxide than those with normal levels. Therefore, soluble syndecan-1 may be related to the development of proliferative vasculopathy in SSc patients. PMID: 26076711 in colorectal adenomas, the heparanase-1 does not participate in syndecan-1 degradation; the heparanase-2 does not stimulate syndecan-1 degradation by the action of heparanase-1, and the heparanase-2 may be involved in the modulation of the heparanase-1 activity. PMID: 26972718 Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts. PMID: 26460958 The new markers were able to identify a clonal CD138-negative population as minimal residual disease in the bone marrow and peripheral blood of MM patients. PMID: 26729247 miR-145 suppresses syndecan-1 and, by this mechanism, up-regulates stem cell factors and induces cell senescence and differentiation. PMID: 26514209 The results suggest that Sdc1 may modulate fibronectin fibrillogenesis and/or alter cell morphology during ECM production through alphavbeta3 integrin, thereby mediating ECM fiber alignment. PMID: 26909794 Syndecan-1 on epithelial tumor cells promotes MIF binding and MIF-mediated cell migration. This may represent a relevant mechanism through which MIF enhances tumor cell motility and metastasis. PMID: 26852939 SULF1 levels are lower in pleural malignancies compared to benign conditions and inversely correlate with the amounts of syndecan-1, suggesting important roles for syndecan-1 and SULF1 in malignant mesothelioma. PMID: 26210886 Our study indicates that SDC1 expressed by the bone marrow microenvironment is involved in angiogenesis in MM. PMID: 25353275 miR-302a plays a key role in inhibition of ovarian cancer cell proliferation, and enhancing apoptosis by targeting SDC1. PMID: 26191180 The concentration of syndecan-1, a marker of glycocalyx damage measured during ED admission, is valuable in assessing the risk of developing AKI and in-hospital mortality. PMID: 25891890 Sdc-1 may act as a modulator of ESC apoptosis and probably invasion depth as a crucial factor for successful pregnancy. PMID: 25830352 Elevated levels of soluble CD138/Sdc-1 in older bladder cancer patients and those with muscular invasion sheds some light on the mechanisms of the disease invasion. PMID: 25115297 demonstrate that HER2 is captured via a site, comprised of amino acids 210-240, in the extracellular domain of human Sdc1, and EGFR is captured via an extracellular site comprised of amino acids 87-131 in human Sdc4 PMID: 26350464 stromal changes in the expression of SDC-1 may originate from the stroma and contribute to the pathogenesis and metastatic potential of epithelial ovarian carcinoma PMID: 26513873 syndecan-1 has a role in glycocalyx shedding and is increased in patients with end-stage liver disease; ischemia-reperfusion injury during OLT further exacerbates glycocalyx shedding PMID: 25757215 Data indicate that the extracellular and cytoplasmic domains of syndecans 1/2/3/4 are intrinsically disordered regions. PMID: 24956062 HPV16 particles binds to heparan sulfate and syndecan-1 molecules present in the extracellular matrix. PMID: 26289843 syndecan-1 may have a role as a biological and prognostic marker in patients with triple-positive breast carcinomas PMID: 25273930 our findings identify heparanase as a modulator of the syndecan-syntenin-ALIX pathway, fostering endosomal membrane budding and the biogenesis of exosomes by trimming the heparan sulfate chains on syndecans PMID: 25732677 Serum SDC-1 levels are increased in systemic lupus erythematosus patients with nephritis, indicating that SDC-1 might be a useful serum biomarker for active LN. PMID: 25512478 Syndecan-1 expression is associated with tumor size and EGFR expression in colorectal carcinoma PMID: 25589885 syndecan-1 in pleural effusions predicted a survival difference for patients with pleural metastatic disease and malignant mesothelioma. PMID: 25147801

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.